Generic Coreg Availability

See also: Generic Coreg CR

Coreg is a brand name of carvedilol, approved by the FDA in the following formulation(s):

COREG (carvedilol - tablet;oral)

  • Manufacturer: SMITHKLINE BEECHAM
    Approval date: September 14, 1995
    Strength(s): 6.25MG [AB], 12.5MG [RLD] [AB], 25MG [AB]
  • Manufacturer: SMITHKLINE BEECHAM
    Approval date: May 29, 1997
    Strength(s): 3.125MG [AB]

Has a generic version of Coreg been approved?

A generic version of Coreg has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Coreg and have been approved by the FDA:

carvedilol tablet;oral

  • Manufacturer: APOTEX INC
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: AUROBINDO PHARMA
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: BEXIMCO USA
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: CIPLA LTD
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: HIKMA
    Approval date: September 7, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: LUPIN
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: MYLAN
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: PLIVA HRVATSKA DOO
    Approval date: October 30, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: RANBAXY
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: SANDOZ
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: SUN PHARM INDS INC
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: TARO
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: TEVA
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: September 5, 2007
    Strength(s): 3.125MG [AB], 6.25MG [AB], 12.5MG [AB], 25MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coreg. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method of treatment for decreasing mortality resulting from congestive heart failure
    Patent RE40000
    Issued: January 8, 2008
    Inventor(s): Lukas-Laskey; Mary Ann & Ruffolo, Jr.; Robert & Shusterman; Neil Howard & Sponer; Gisbert & Strein; Klaus
    Assignee(s): SB Pharmco Puerto Rico Inc.
    A method of treatment using a compound of Formula I: wherein: R1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R3 is hydrogen or lower alkyl of up to 6 carbon atoms; R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent —CH2—O—; X is a valency bond, —CH2, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronapthyl; R5 and R6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a —CONH2— group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and digoxin for decreasing mortality resulting from congestive heart failure (CHF) in mammals, particularly humans.
    Patent expiration dates:
    • June 7, 2015
      ✓ 
      Patent use: DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
    • December 7, 2015
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web1)